Volume 4, Issue 5, September 2019, Page: 79-86
Epidemiological Profile of Thrombophilia in Marrakech (Morocco): About 200 Cases
Ilham Karrati, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Hanane Mouhib, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Hicham Yahyaoui, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Radia Amaddah, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Mustapha Aitameur, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Mohamed Chakour, Haematology Laboratory of Avicenne Military Hospital, University Hospital Mohamed VI, Marrakech, Morocco
Received: Jul. 31, 2019;       Accepted: Aug. 30, 2019;       Published: Sep. 19, 2019
DOI: 10.11648/j.ajlm.20190405.11      View  58      Downloads  20
Abstract
Thrombophilia is a situation characterized by an increased tendency to thrombosis. The main objective of this work is to report on the experience of the Haematology Laboratory of the Avicenne Military Hospital of Marrakech, through a retrospective descriptive study carried out over a period of 9 years, on 200 requests for a thrombophilia check-up; and secondly, to discuss its indications and interest in the etiological diagnosis of unexplained thrombosis in the light of the latest recommendations. The thrombogenic risk factor most commonly found in our study was PS deficiency, in contrast to the predominance of Factor V mutation in Western countries, hence the importance of emphasizing that in clinical practice, the first-line thrombophilia assessment should always combine, in accordance with the latest recommendations: inhibitor deficiencies, F V and F II mutations, antiphospholipid antibodies and possibly F VIII determination.
Keywords
Thrombophilia Assessment, Protein C, Protein S, Antithrombin, Factor V mutation, Factor II Mutation
To cite this article
Ilham Karrati, Hanane Mouhib, Hicham Yahyaoui, Radia Amaddah, Mustapha Aitameur, Mohamed Chakour, Epidemiological Profile of Thrombophilia in Marrakech (Morocco): About 200 Cases, American Journal of Laboratory Medicine. Vol. 4, No. 5, 2019, pp. 79-86. doi: 10.11648/j.ajlm.20190405.11
Copyright
Copyright © 2019 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
Seligsohn U, Lubetsky A. Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-31.
[2]
Bauer KA. The thrombophilias: well–defind risk factors with uncertain therapeutic implications. Ann Intern Med 2001; 135: 367-73.
[3]
Outuraud F. Durée optimale du traitement anticoagulant au décours d’une embolie pulmonaire. RevuedesMaladiesRespiratoires (2011) 28: 1265—1277.
[4]
Connors JM. Thrombophilia testing and venous thrombosis. N Engl J Med. 2017; 377 (12): 1177-87.
[5]
Baglin T, Gray E, Greaves M, et al. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209–20.
[6]
Nicolaides AN, Breddin HK, Carpenter P, et al. Thrombophilia and venous thromboembolism. Internationalconsensus statement. Guidelines according to scientific evidence. IntAngiol 2005; 24: 1–26.
[7]
Kearon C, Akl EA, Comerota AJ, et al. Antithrombotic therapyfor VTE disease: Antithrombotic Therapy and Prevention ofThrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141: e419S–94S.
[8]
Konstantinides SV, Torbicki A, Agnelli G, et al.2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J 2014; 35: 3033–69.
[9]
Pernod G, Biron-Andreani C, Morange PE, et al. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34: 156–203.
[10]
Emmerich J. How to assess thrombophilia and which one ?Rev Prat 2007; 57 (7): 714—5.
[11]
Caprini JA, Goldshteyn S, Glase CJ, Hathaway K. Thrombophilia testing in patients with venous thrombosis. Eur J Vasc Endovasc Surg 2005; 30: 550–5.
[12]
Martinelli I, Battaglioli T, Razzari C, Manucci PM. Type and location of venous thromboembolism in patients with factor V Leiden or prothrombin G20210A and in those with no thrombophilia. J ThrombHaemost 2007; 5: 98–101.
[13]
Righini M, Paris S, Le Gal G, Laroche JP, Perrier A. Bounameaux H. Clinical relevance of distal deep vein thrombosis. Review of literature data. ThrombHaemost 2006; 95: 56–64.
[14]
J.-S. Allaina, P. Gueret b, T. Le Galloua, C. Cazalets a, A. Lescoat a, P. JegoaaService de médecine interne, CHU hôpital Sud, 16, boulevard de Bulgarie, 35203 Rennes, France.
[15]
Pernod G B-AC, Morange PE, Boehlen F, Constans J, Couturaud F, Drouet L, Jude B, Lecompte T, Le Gal G, Trillot N, Wahl DRecommandations pour la recherche de facteurs biologiques de risque dans le cadre de la maladie thromboembolique veineuse. Recommandations GEHT-SFMV 2008. J Mal Vasc 2009; 34: 90.
[16]
Zmazen R, Guermazi S, KarouiMAssociation de deux facteurs de risque thrombotique: Facteur V leiden et hyperhomocystéinemie, à propos d’un cas. Pathologiebiologie 2006.
[17]
Kottke-Marchant K, Duncan A. Antithrombindeficiency: issues in laboratory diagnosis. Arch Pathol Lab Med 2002; 126: 1326–36.
[18]
Jude B., Susen, S., Trillot N., Zawadzki C. Les thrombophilies constitutionnelles, Laboratoire d'Hématologie, Hôpital Cardiologique, CHRU, Lille.
[19]
Roux, A., Sanchez, O., & Meyer, G. Quel bilan de thrombophilie chez un patient atteint de maladie veineuse thromboembolique? Réanimation, 17 (4), 355–362. doi: 10.1016/j.reaurg.2008.03.011.
[20]
Pabinger I, Schneider B. Thrombotic risk in hereditary antithrombin III, protein C, or protein S deficiency. A cooperative, retrospective study. Gesellschaft fur Thrombose-und Hamostaseforschung (GTH) study group on natural inhibitors. ArteriosclerThrombVascBiol 1996; 16: 742—8.
[21]
Bontempo F. A. The Lupus Anticoagulant –An UpdateMay, 2001; Transfusion Medicine Updates.
[22]
Galli M, et al. Lupus anticoagulants are stronger risk factors for thrombosis than anticardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003; 101 (5): 1827—32.
[23]
Koster T, Blann AD, Briet E, Vandenbroucke JP, Rosendaal FR. Role of clotting factor VIII in effect of von Willebrand factor on occurrence of deep-vein thrombosis. Lancet 1995; 345: 152–5.
[24]
Kraaijenhagen RA, In’t Anker PS, Koopman MMW, Reitsma PH, Prins MH, Van den Ende A, et al. High plasma concentration of factor VIIIc is a major risk factor for venous thromboembolism. ThrombHaemost 2000; 83: 5–9.
[25]
O’Donnell J, Tuddenham EGD, Manning R, Kemball C, Johnson D, Laffan M. High prevalence of elevated factor VIII levels in patients referred for thrombophilia screening: role of increased synthesis and relationship to the acute phase reaction. ThrombHaemost 1999; 81: 680–3.
[26]
O’Donnell J, Mumford AD, Manning RA, Laffan M. Elevation of FVIIIc in venous thromboembolism is persistent and independent of the acute phase response. ThrombHaemost 2000; 83: 10–3.
[27]
Bloemenkamp KWM, Helmerhorst FM, Rosendaal FR, Vandenbroucke JP. Venous thrombosis, oral contraceptives and high factor VIII levels. Thromb Haemost 1999; 82: 1024–7.
[28]
De Mitrio V, Marino R, Scaraggi FA, Di Bari L, Giannoccaro F, Petronelli M, et al. Influence of factor VIII/von Willebrand complex on the activated protein C resistance phenotype and on the risk for venous thromboembolism in heterozygous carriers of the factor V Leiden mutation. Blood CoagulFibrinol 1999; 10: 409–16.
[29]
Rees DC. World distribution of factor V Leiden, PMID: 7475606, [PubMed - indexed for MEDLINE], Lancet. 1995 Oct 28; 346 (8983): 1133-4.
[30]
Rosendaal FR, Koster T, Vandenbroucke JP, Reitsma PH. High risk of thrombosis in patients homozygous forfactor V Leiden (activated protein C resistance).
[31]
Allain J. S, Gueret. P, Le Gallou. T, Cazalets. C, Lescoat. A, Jego. PLa recherche de thrombophilie héréditaire et son impact thérapeutique dans la maladie thromboembolique veineuse: résultats d’une étude monocentrique rétrospective sur 162patientsLa Revue de Médecine Interne; Volume 36, Supplement 2, December 2015, Page A58.
Browse journals by subject